Attached files

file filename
10-Q/A - LIGHTLAKE THERAPEUTICS INC. 10-Q/A - OPIANT PHARMACEUTICALS, INC.a6214174.txt
EX-32.1 - EXHIBIT 32.1 - OPIANT PHARMACEUTICALS, INC.a6214174ex32_1.txt
EX-31.1 - EXHIBIT 31.1 - OPIANT PHARMACEUTICALS, INC.a6214174ex31_1.txt
EX-32.2 - EXHIBIT 32.2 - OPIANT PHARMACEUTICALS, INC.a6214174ex32_2.txt

EXHIBIT  31.2

                                 CERTIFICATION
                           Pursuant to 18 U.S.C. 1350
                (Section 302 of the Sarbanes-Oxley Act of 2002)

I,  Seijin  Ki,  Chief Financial Officer of Lightlake Therapeutics Inc., certify
that:

1.   I  have  reviewed  this  Quarterly  Report  on  Form  10-Q/A  of  Lightlake
Therapeutics  Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of
a  material  fact  or  omit  to  state  a  material  fact  necessary to make the
statements  made, in light of the circumstances under which such statements were
made,  not  misleading  with  respect  to  the  period  covered  by this report;

3.   Based  on  my  knowledge,  the  financial  statements,  and other financial
information included in this report, fairly present in all material respects the
financial  condition,  results of operations and cash flows of the registrant as
of,  and  for,  the  periods  presented  in  this  report;

4.   The  registrant's  other  certifying  officer(s)  and I are responsible for
establishing  and  maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over  financial
reporting  (as  defined  in  Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant  and  have:

     a)   Designed such disclosure controls and procedures, or caused such
          disclosure controls and procedures to be designed under our
          supervision, to ensure that material information relating to the
          registrant, including its consolidated subsidiaries, is made known to
          me by others within those entities, particularly during the period in
          which this report is being prepared;

     b)   Designed such internal control over financial reporting, or
          caused such internal control over financial reporting to be designed
          under our supervision, to provide reasonable assurance regarding the
          reliability of financial reporting and the preparation of financial
          statements for external purposes in accordance with generally accepted
          accounting principles;

     c)   Evaluated the effectiveness of the registrant's disclosure
          controls and procedures and presented in this report our conclusions
          about the effectiveness of the disclosure controls and procedures, as
          of the end of the period covered by this report based on such
          evaluation; and

     d)   Disclosed in this report any change in the registrant's internal
          control over financial reporting that occurred during the registrant's
          most recent fiscal quarter (the registrant's fourth fiscal quarter in
          the case of an annual report) that has materially affected, or is
          reasonably likely to materially affect, the registrant's internal
          control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on
our  most recent evaluation of internal control over financial reporting, to the
registrant's  auditors  and  the  audit  committee  of the registrant's board of
directors  (or  persons  performing  the  equivalent  functions):

     a)   All significant deficiencies and material weaknesses in the
          design or operation of internal control over financial reporting which
          are reasonably likely to adversely affect the registrant's ability to
          record, process, summarize and report financial information; and

     b)   Any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal control over financial reporting.


Date:  3/15/10                               By:  /s/ Seijin Ki
                                                  ------------------------------
                                                  Seijin Ki
                                                  Chief Financial Office